Document is current

Any future updates will be listed below

Safety assessments and clinical features of PARP inhibitors from real-world data of Japanese patients with ovarian cancer

Crossref DOI link: https://doi.org/10.1038/s41598-024-63600-z

Published Online: 2024-06-01

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark